Plain-English translation of NCT07129382 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called CS32582 to see if it can help people with moderate to severe plaque psoriasis (a chronic skin condition with thick, scaly patches). The study involves two phases: first, researchers will test different doses in a small group to make sure the medication is safe, and then a larger group will receive the medication for 12 weeks to measure how well it works.
Current treatments for moderate to severe psoriasis don't work well enough for everyone, and some people experience side effects or don't tolerate existing options. This trial is exploring whether this new medication could offer a safer or more effective alternative.
You likely qualify if…
You likely don't qualify if…
You will receive capsules to take twice daily, either the new medication at one of several doses or a placebo (inactive capsule) — you won't know which one you're taking. Depending on which phase you join, you'll take the capsules for either 4 weeks or 12 weeks while researchers monitor your skin, check your blood work, and ask about any side effects you experience. You'll attend clinic visits throughout the trial so doctors can assess how your psoriasis improves and ensure the medication is safe for you.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China